Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A stronger nicotine patch might break the dual Smoking-Vaping habit

NCT ID NCT07754578

Prevention Sponsor: Medical University of South Carolina Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This trial tests whether higher doses of nicotine replacement therapy (NRT) can help adults who use both cigarettes and e-cigarettes quit both products. Participants are randomly assigned to receive either standard-dose NRT, augmented-dose NRT, or no NRT, with all groups getting behavioral support. The study measures whether people achieve biochemically confirmed abstinence from both products at 12 and 24 weeks, and also looks at DNA damage biomarkers related to tobacco use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nicotine replacement therapy (nicotine patch and lozenge) at standard or augmented doses, plus behavioral support
What this could lead to
If successful, this could establish a more effective way to help people quit both cigarettes and e-cigarettes, potentially lowering cancer risk and improving long-term health.
What could go wrong
The trial is in Phase 2, so results are preliminary. Higher doses may cause more side effects, and quitting both products is challenging, so success rates may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 321 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jul 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age 18+; * report nicotine-containing e-cigarette use 5+ times per day, \>5 days per week, for \> 6 months; * smoking \>1 cigarette per day, \>5 days per week, for \>6 months; * interest in quitting cigarettes and e-cigarettes within the next month (\>6 on 10-point scale); * willing to try nicotine replacement therapy; * access to text/internet/email. Exclusion Criteria: * report use of other tobacco or nicotine products (i.e., pouches, smokeless tobacco, hookah) \>1 time per week in the past 3 months; * have medical contraindications for nicotine replacement therapy use (patch and lozenge; e.g., recent myocardial infarction, arrhythmias, angina, vascular disease, or medical conditions in which consumption of phenylalanine is contraindicated such as PKU); * report current use of smoking cessation medications (varenicline, bupropion, other nicotine replacement therapies); * endorse symptoms of Cannabis Use Disorder (using the CUDIT assessment); * unable to consent (e.g., cognitive deficit, non-English speaking); * live outside the US.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer prevention behavior are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

nicotine dependence Smoking Vaping

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer prevention behavior Dual use of cigarettes and E-cigarettes E-cigarette cessation Smoking cessation Tobacco cessation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.